LKFT

Lakefront Biotherapeutics NV ADR

33.93

Nov 12 • 3:59 PM ET +0.59 (1.77%)

34.00

Aftermarket • 7:30 PM ET +0.07 (0.21%)

Healthcare Biotechnology Belgium Mid NASD

Nov 11, 9:50 PMLakefront Biotherapeutics NV ADR reports fiscal quarterly results with non-GAAP EPS $-0.37 (+87% YoY) and revenue $5.9M (-93% YoY), beats estimates

Peers: LEGN AUTL ALLO JANX CRBU SANA ARGX ARTV CABA FATE

| Held by: IBB SBIO AVDE APIE AVDS QQQS IBBQ BIB

Scroll to Statements

Index	-
Market Cap	2.23B
Enterprise Value	-325.37M
Income	693.58M
Sales	1.15B
Book/sh	56.83
Cash/sh	39.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	452
IPO	Jul 07, 2008

P/E	3.22
Forward P/E	-
PEG	-
P/S	1.93
P/B	0.60
P/C	0.87
P/FCF	-
EV/EBITDA	-
EV/Sales	-0.28
Quick Ratio	32.70
Current Ratio	32.82
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	10.52
EPS next Y	-2.51
EPS next Q	-0.75
EPS this Y	-146.39%
EPS next Y	5.76%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	70.43% 18.16%
EPS Y/Y TTM	323.94%
Sales Y/Y TTM	285.48%
EPS Q/Q	101.92%
Sales Q/Q	-80.97%
Earnings	Nov 11 AMC
EPS/Sales Surpr.	0.00% 0.00%

Insider Own	25.35%
Insider Trans	0.00%
Inst Own	24.17%
Inst Trans	0.48%
ROA	16.62%
ROE	20.22%
ROIC	18.56%
Gross Margin	97.45%
Oper. Margin	59.54%
Profit Margin	60.14%
SMA20	5.42%
SMA50	12.12%
SMA200	13.53%
Trades

Shs Outstand	65.66M
Shs Float	49.01M
Short Float	2.65%
Short Ratio	4.55
Short Interest	1.30M
52W High	36.24 -6.37%
52W Low	25.68 32.13%
Volatility	3.08% 2.43%
ATR (14)	0.92
RSI (14)	71.13
Beta	0.21
Rel Volume	1.87
Avg Volume	285.70K
Volume	535,540

Perf Week	1.10%
Perf Month	15.41%
Perf Quarter	23.25%
Perf Half Y	23.43%
Perf YTD	3.76%
Perf Year	5.01%
Perf 3Y	-6.63%
Perf 5Y	-35.76%
Perf 10Y	-43.03%
Recom	2.50
Target Price	34.49
Prev Close	33.34
Price	33.93
Change %	1.77%

Consensus

Buy

Avg. Price Target

$34.49

Implied Upside

+1.7%

Analysts11incl. previous ratings

Rating Distribution3 Buy · 5 Hold · 3 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 20, 2026	Resumed	MMorgan Stanley	Equal-Weight	$26	-23.4%
Sep 23, 2026	Upgrade	RRBC Capital Mkts	Sector Perform → Outperform	$45	+32.6%
Aug 21, 2026	Initiated	TTD Cowen	Buy
Jul 10, 2026	Resumed	MMorgan Stanley	Equal-Weight	$30	-11.6%
Oct 22, 2025	Upgrade	LLeerink Partners	Market Perform → Outperform	$40	+17.9%
Aug 05, 2025	Downgrade	DDeutsche Bank	Hold → Sell
Feb 14, 2025	Downgrade	MMorgan Stanley	Equal-Weight → Underweight	$31 → $22	-35.2%
Nov 20, 2024	Downgrade	KKepler	Hold → Reduce
Sep 09, 2024	Initiated	LLeerink Partners	Market Perform	$24	-29.3%
Aug 02, 2024	Downgrade	RRaymond James	Outperform → Mkt Perform
Mar 28, 2024	Downgrade	BBofA Securities	Neutral → Underperform	$41 → $31	-8.6%
Mar 07, 2024	Resumed	MMorgan Stanley	Equal-Weight	$38	+12.0%
Aug 24, 2023	Downgrade	CCitigroup	Buy → Neutral
May 05, 2023	Upgrade	RRaymond James	Mkt Perform → Outperform
Jan 23, 2023	Upgrade	JJefferies	Underperform → Hold	$49 → $47.20	+39.1%
Nov 07, 2022	Downgrade	RRaymond James	Outperform → Mkt Perform
Sep 09, 2022	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$80 → $61	+79.8%
Jan 27, 2022	Upgrade	CCitigroup	Neutral → Buy
Aug 19, 2021	Downgrade	BBarclays	Overweight → Equal Weight
Aug 06, 2021	Downgrade	DDeutsche Bank	Buy → Hold

Oct-15-26 11:55AM	Belgian startup revives Galapagos CAR-T research (BioPharma Dive)
Sep-23-26 09:49AM	Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls (The Fly)
Aug-10-26 09:17AM	Earnings To Watch: Lakefront Biotherapeutics NV (XAMS:LKFT) Q2 2026 -- GF Value Sees 474% Upside (GuruFocus.com)
Aug-07-26 09:17AM	Earnings To Watch: Lakefront Biotherapeutics NV (XAMS:LKFT) Q2 2026 -- GF Value Sees 496% Upside (GuruFocus.com)
Jun-04-26 04:15PM	Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline (Business Wire)
08:03AM	Loading…
Mar-24-26 08:03AM	Gilead to Buy Ouro Medicines for $2.2 Billion. 'Immune Reset' Is Key to Future Gains. (Barrons.com) -6.58%
Mar-23-26 06:58PM	Gilead to buy Ouro Medicines for up to $2.2 billion (Investing.com)
Feb-24-26 02:01PM	Galapagos NV (GLPG) Full Year 2025 Earnings Call Highlights: Strategic Shifts and Financial ... (GuruFocus.com)
11:47AM	Galapagos Q4 Earnings Call Highlights (MarketBeat)
Feb-23-26 07:22AM	Galapagos NV (XAMS:GLPG) Q4 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Nov-06-25 02:06PM	Galapagos NV (GLPG) Q3 2025 Earnings Call Highlights: Navigating Strategic Shifts Amidst ... (GuruFocus.com)
Sep-11-25 11:18AM	Galapagos NV (GLPG)' CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial (Insider Monkey)
Aug-07-25 04:01PM	Galapagos Creates New Subscription Right Plan (GlobeNewswire)
Aug-06-25 01:30AM	Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (GlobeNewswire)
Jul-23-25 04:03PM	Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation (GlobeNewswire) -7.33%
04:02PM	Loading…
04:02PM	Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors (GlobeNewswire)
04:01PM	Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update (GlobeNewswire)
Jun-23-25 01:30AM	Galapagos Appoints Aaron Cox as Chief Financial Officer (GlobeNewswire)
Jun-18-25 04:01PM	Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101 (GlobeNewswire)
Jun-12-25 04:01PM	Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL (GlobeNewswire)
May-27-25 04:33PM	Galapagos Creates New Subscription Right Plan (GlobeNewswire)
May-14-25 04:01PM	Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 (GlobeNewswire)
May-13-25 01:36AM	Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes (GlobeNewswire) +7.06%
Apr-25-25 06:16PM	Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101 (Seeking Alpha)
Apr-24-25 11:34AM	Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript (Seeking Alpha)
Apr-23-25 04:01PM	Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts (GlobeNewswire)
Apr-21-25 04:10PM	Galapagos Announces Executive Leadership Updates (GlobeNewswire)
Apr-15-25 01:30AM	Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025 (GlobeNewswire)
Apr-11-25 03:05PM	Is Galapagos (GLPG) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
04:01PM	Loading…
Mar-27-25 04:01PM	Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting (GlobeNewswire)
Feb-24-25 04:01PM	Galapagos to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-17-25 04:01PM	Galapagos receives transparency notification and 13D filing from Tang Capital (GlobeNewswire)
Feb-12-25 04:01PM	Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update (GlobeNewswire) +7.21%
Jan-08-25 01:30AM	Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities (GlobeNewswire)
Jan-07-25 04:01PM	Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-24 12:30PM	Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (GlobeNewswire)
Nov-05-24 04:01PM	Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 (GlobeNewswire)
Oct-30-24 04:01PM	Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.52%
Oct-07-24 01:00AM	Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth (GlobeNewswire)
Sep-30-24 04:01PM	Galapagos receives transparency notification from EcoR1 Capital (GlobeNewswire)
Sep-16-24 04:01PM	Galapagos receives transparency notification from EcoR1 Capital (GlobeNewswire)
Sep-03-24 04:01PM	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
Aug-23-24 01:00AM	Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (GlobeNewswire)
Aug-20-24 04:01PM	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
Aug-01-24 04:01PM	Galapagos reports half-year 2024 financial results and provides second quarter business update (GlobeNewswire) -5.09%
04:01PM	BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology (PR Newswire)
Jun-25-24 05:53AM	GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
Jun-14-24 04:01PM	Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 (GlobeNewswire)
May-30-24 04:01PM	Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications (GlobeNewswire)
04:01PM	Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications (Newsfile)
May-16-24 04:01PM	Galapagos creates new subscription right plans (GlobeNewswire)
May-15-24 04:01PM	Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S. (GlobeNewswire)
May-06-24 10:47AM	Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 04:01PM	Galapagos reports first quarter 2024 financial results (GlobeNewswire)
Apr-30-24 04:01PM	Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024 (GlobeNewswire)
Apr-24-24 09:35AM	Down -9.97% in 4 Weeks, Here's Why You Should You Buy the Dip in Galapagos (GLPG) (Zacks)
Apr-04-24 04:01PM	Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 (GlobeNewswire)
Apr-03-24 09:35AM	After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG) (Zacks)
Mar-28-24 04:01PM	Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings (GlobeNewswire)
Mar-26-24 04:01PM	Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board (GlobeNewswire)
Mar-18-24 09:35AM	Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround (Zacks)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-24-24 08:30AM	Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 04:01PM	Galapagos announces full year 2023 results and outlook for 2024 (GlobeNewswire) -8.28%
04:01PM	Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline (GlobeNewswire)
Feb-15-24 04:01PM	Galapagos presents at EBMT-EHA annual meeting 2024 (GlobeNewswire)
Feb-05-24 07:00AM	NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer (GlobeNewswire)
Jan-31-24 04:01PM	Galapagos completes transaction to transfer Jyseleca business to Alfasigma (GlobeNewswire)
Jan-04-24 04:01PM	Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S. (GlobeNewswire)
Jan-03-24 04:01PM	Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology (GlobeNewswire)
04:01PM	BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets (PR Newswire)
Jan-02-24 01:00AM	Galapagos signs agreement to transfer Jyseleca business to Alfasigma (GlobeNewswire)
Dec-19-23 04:01PM	Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301 (GlobeNewswire)
Dec-09-23 12:00PM	Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 (GlobeNewswire)
Dec-07-23 04:01PM	Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023 (GlobeNewswire)
Nov-06-23 10:32AM	Galapagos NV (NASDAQ:GLPG) Q3 2023 Earnings Call Transcript (Insider Monkey)
07:45AM	Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care (PR Newswire)
Nov-02-23 04:01PM	Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023 (GlobeNewswire) +7.33%
Oct-30-23 04:01PM	Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma (GlobeNewswire)
Sep-19-23 04:01PM	Galapagos appoints Simon Sturge to its Board of Directors (GlobeNewswire)
Aug-28-23 04:01PM	Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus (GlobeNewswire)
Aug-03-23 04:01PM	Galapagos announces first half-year 2023 financial results (GlobeNewswire)
Jun-15-23 04:01PM	Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer (GlobeNewswire)
Jun-12-23 04:01PM	Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board (GlobeNewswire)
Jun-05-23 04:01PM	Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress (GlobeNewswire)
May-23-23 04:01PM	Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis (GlobeNewswire)
May-22-23 04:01PM	Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023 (GlobeNewswire)
May-05-23 04:01PM	Galapagos creates new subscription right plans (GlobeNewswire) +5.90%
May-04-23 04:01PM	Galapagos announces first quarter 2023 financial results (GlobeNewswire)
May-02-23 04:01PM	Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer (GlobeNewswire)
Apr-26-23 04:01PM	Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis (GlobeNewswire)
Apr-25-23 04:01PM	Galapagos shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders meeting (GlobeNewswire)
Mar-30-23 04:30PM	Galapagos and NovAliX enter into an integrated drug discovery collaboration (GlobeNewswire)
Mar-23-23 04:01PM	Galapagos publishes 2022 annual report and announces Annual Shareholders Meeting (GlobeNewswire)
Mar-20-23 04:01PM	Galapagos increases share capital through subscription right exercises (GlobeNewswire)
Feb-27-23 04:01PM	Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023 (GlobeNewswire)
Feb-23-23 04:01PM	Galapagos announces full year 2022 results and outlook for 2023 (GlobeNewswire)
Feb-09-23 04:01PM	Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL (GlobeNewswire) -7.34%
Feb-08-23 04:01PM	Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohns disease (GlobeNewswire)

Show Previous News

Lakefront Biotherapeutics is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

CEO & Executive DirectorMr. Henry O. Gosebruch

Chief Financial OfficerMr. Aaron L. Cox

Chief Operating OfficerMs. Christina Carlson J.D.

Pharm. D.Dr. Glenn Schulman M.P.H.

Executive VP & General CounselMr. Fred W. Blakeslee II

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

LKFT

Lakefront Biotherapeutics NV ADR

Upgrade your Finviz experience

All the Features.
Half the Price.